Corps d'inclusion : Questions médicales fréquentes
Nom anglais: Inclusion Bodies
Descriptor UI:D002479
Tree Number:A11.284.420
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Corps d'inclusion : Questions médicales les plus fréquentes",
"headline": "Corps d'inclusion : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Corps d'inclusion : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-14",
"dateModified": "2026-04-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Corps d'inclusion"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Structures cellulaires",
"url": "https://questionsmedicales.fr/mesh/D022082",
"about": {
"@type": "MedicalCondition",
"name": "Structures cellulaires",
"code": {
"@type": "MedicalCode",
"code": "D022082",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.284"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Corps d'inclusion intranucléaire",
"alternateName": "Intranuclear Inclusion Bodies",
"url": "https://questionsmedicales.fr/mesh/D045586",
"about": {
"@type": "MedicalCondition",
"name": "Corps d'inclusion intranucléaire",
"code": {
"@type": "MedicalCode",
"code": "D045586",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.284.420.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Corps de Lewy",
"alternateName": "Lewy Bodies",
"url": "https://questionsmedicales.fr/mesh/D016631",
"about": {
"@type": "MedicalCondition",
"name": "Corps de Lewy",
"code": {
"@type": "MedicalCode",
"code": "D016631",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.284.420.460"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Corps de Mallory",
"alternateName": "Mallory Bodies",
"url": "https://questionsmedicales.fr/mesh/D059609",
"about": {
"@type": "MedicalCondition",
"name": "Corps de Mallory",
"code": {
"@type": "MedicalCode",
"code": "D059609",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.284.420.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Corps d'inclusion",
"alternateName": "Inclusion Bodies",
"code": {
"@type": "MedicalCode",
"code": "D002479",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elena Garcia-Fruitós",
"url": "https://questionsmedicales.fr/author/Elena%20Garcia-Fruit%C3%B3s",
"affiliation": {
"@type": "Organization",
"name": "Department of Ruminant Production, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Caldes de Montbui, Spain. elena.garcia@irta.cat."
}
},
{
"@type": "Person",
"name": "Oliver Spadiut",
"url": "https://questionsmedicales.fr/author/Oliver%20Spadiut",
"affiliation": {
"@type": "Organization",
"name": "Research Division Integrated Bioprocess Development, TU Wien Institute of Chemical, Environmental, and Bioscience Engineering, Vienna, Austria. oliver.spadiut@tuwien.ac.at."
}
},
{
"@type": "Person",
"name": "Anna Arís",
"url": "https://questionsmedicales.fr/author/Anna%20Ar%C3%ADs",
"affiliation": {
"@type": "Organization",
"name": "Department of Ruminant Production, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Caldes de Montbui, Spain. anna.aris@irta.cat."
}
},
{
"@type": "Person",
"name": "Julian Kopp",
"url": "https://questionsmedicales.fr/author/Julian%20Kopp",
"affiliation": {
"@type": "Organization",
"name": "Research Division Integrated Bioprocess Development, TU Wien Institute of Chemical, Environmental, and Bioscience Engineering, Vienna, Austria. julian.kopp@tuwien.ac.at."
}
},
{
"@type": "Person",
"name": "Elie Naddaf",
"url": "https://questionsmedicales.fr/author/Elie%20Naddaf",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Mayo Clinic, Rochester, MN, USA. naddaf.elie@mayo.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Exploring challenges in the management and treatment of inclusion body myositis.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37503813",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/BOR.0000000000000958"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum-Circulating microRNAs in Sporadic Inclusion Body Myositis.",
"datePublished": "2023-07-06",
"url": "https://questionsmedicales.fr/article/37446317",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241311139"
}
},
{
"@type": "ScholarlyArticle",
"name": "Case report of a family with hereditary inclusion body myopathy with",
"datePublished": "2023-12-11",
"url": "https://questionsmedicales.fr/article/38146440",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fneur.2023.1290960"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mitochondrial defects in sporadic inclusion body myositis-causes and consequences.",
"datePublished": "2024-05-14",
"url": "https://questionsmedicales.fr/article/38808223",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fcell.2024.1403463"
}
},
{
"@type": "ScholarlyArticle",
"name": "Update on the evaluation and management of dysphagia in sporadic inclusion body myositis.",
"datePublished": "2023-09-01",
"url": "https://questionsmedicales.fr/article/37678324",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MOO.0000000000000922"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures cellulaires",
"item": "https://questionsmedicales.fr/mesh/D022082"
},
{
"@type": "ListItem",
"position": 4,
"name": "Corps d'inclusion",
"item": "https://questionsmedicales.fr/mesh/D002479"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Corps d'inclusion - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Corps d'inclusion",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-04-28",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Corps d'inclusion",
"description": "Comment diagnostique-t-on les corps d'inclusion ?\nQuels tests sont utilisés pour identifier les corps d'inclusion ?\nLes corps d'inclusion sont-ils visibles à l'imagerie ?\nQuels signes histologiques indiquent des corps d'inclusion ?\nPeut-on détecter des corps d'inclusion dans le sang ?",
"url": "https://questionsmedicales.fr/mesh/D002479?page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Corps d'inclusion",
"description": "Quels symptômes sont associés aux corps d'inclusion ?\nLes corps d'inclusion causent-ils des symptômes spécifiques ?\nLes corps d'inclusion sont-ils liés à des infections ?\nPeut-on avoir des corps d'inclusion sans symptômes ?\nLes corps d'inclusion affectent-ils la fonction cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D002479?page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Corps d'inclusion",
"description": "Comment prévenir les infections liées aux corps d'inclusion ?\nY a-t-il des mesures préventives spécifiques ?\nLes corps d'inclusion peuvent-ils être évités ?\nLes vaccinations aident-elles contre les corps d'inclusion ?\nL'éducation sanitaire est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D002479?page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Corps d'inclusion",
"description": "Quel traitement est recommandé pour les corps d'inclusion ?\nLes corps d'inclusion nécessitent-ils une intervention chirurgicale ?\nLes médicaments peuvent-ils réduire les corps d'inclusion ?\nY a-t-il des traitements spécifiques pour les corps d'inclusion ?\nLes thérapies géniques peuvent-elles aider ?",
"url": "https://questionsmedicales.fr/mesh/D002479?page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Corps d'inclusion",
"description": "Quelles complications peuvent survenir avec les corps d'inclusion ?\nLes corps d'inclusion peuvent-ils causer des cancers ?\nComment les corps d'inclusion affectent-ils la santé ?\nLes corps d'inclusion entraînent-ils des douleurs ?\nLes corps d'inclusion peuvent-ils affecter le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D002479?page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Corps d'inclusion",
"description": "Quels sont les facteurs de risque des corps d'inclusion ?\nL'âge influence-t-il le risque de corps d'inclusion ?\nLes maladies auto-immunes augmentent-elles le risque ?\nLe mode de vie influence-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D002479?page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on les corps d'inclusion ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par biopsie et analyse histologique des tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour identifier les corps d'inclusion ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunohistochimiques et des colorations spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion sont-ils visibles à l'imagerie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne sont généralement pas visibles à l'imagerie standard, mais peuvent être détectés par biopsie."
}
},
{
"@type": "Question",
"name": "Quels signes histologiques indiquent des corps d'inclusion ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agrégats cytoplasmiques ou nucléaires anormaux sont des indicateurs clés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des corps d'inclusion dans le sang ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils sont généralement présents dans les tissus et non dans le sang."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés aux corps d'inclusion ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon la maladie sous-jacente, incluant fatigue et douleurs."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion causent-ils des symptômes spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils sont souvent des marqueurs de maladies, pas des causes de symptômes."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion sont-ils liés à des infections ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont souvent associés à des infections virales comme le virus de l'herpès."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des corps d'inclusion sans symptômes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être présents sans provoquer de symptômes cliniques apparents."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion affectent-ils la fonction cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent perturber la fonction cellulaire et entraîner des dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections liées aux corps d'inclusion ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vaccination et l'hygiène personnelle sont essentielles pour prévenir les infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le contact avec des personnes infectées et pratiquer une bonne hygiène."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion peuvent-ils être évités ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne peuvent pas être évités, mais les infections sous-jacentes peuvent l'être."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles contre les corps d'inclusion ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations peuvent réduire le risque d'infections associées."
}
},
{
"@type": "Question",
"name": "L'éducation sanitaire est-elle importante ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur les infections et leur prévention est cruciale."
}
},
{
"@type": "Question",
"name": "Quel traitement est recommandé pour les corps d'inclusion ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la maladie sous-jacente, souvent antiviral ou symptomatique."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion nécessitent-ils une intervention chirurgicale ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, sauf si des complications graves ou des tumeurs sont présentes."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils réduire les corps d'inclusion ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments antiviraux peuvent aider à réduire leur formation dans les infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les corps d'inclusion ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique, la gestion se concentre sur la maladie sous-jacente."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques peuvent-elles aider ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours, mais les thérapies géniques ne sont pas encore standardisées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les corps d'inclusion ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des infections chroniques ou des tumeurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion peuvent-ils causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont associés à certains cancers, mais ne sont pas des causes directes."
}
},
{
"@type": "Question",
"name": "Comment les corps d'inclusion affectent-ils la santé ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent perturber la fonction cellulaire et entraîner des maladies dégénératives."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion entraînent-ils des douleurs ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être associés à des douleurs si des tissus environnants sont affectés."
}
},
{
"@type": "Question",
"name": "Les corps d'inclusion peuvent-ils affecter le système immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent influencer la réponse immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque des corps d'inclusion ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections virales, l'immunodépression et certaines maladies génétiques sont des facteurs."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de corps d'inclusion ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées sont plus susceptibles de développer des corps d'inclusion."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes augmentent-elles le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies auto-immunes peuvent augmenter le risque de formation de corps d'inclusion."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque d'infections et de corps d'inclusion."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies peuvent augmenter le risque de corps d'inclusion."
}
}
]
}
]
}
This review provides an overview of the management and treatment landscape of inclusion body myositis (IBM), while highlighting the current challenges and future directions....
IBM is a slowly progressive myopathy that predominantly affects patients over the age of 40, leading to increased morbidity and mortality. Unfortunately, a definitive cure for IBM remains elusive. Var...
Addressing the obstacles encountered by patients with IBM and the medical community presents a multitude of challenges. Effectively surmounting these hurdles requires embracing cutting-edge research s...
Sporadic inclusion body myositis (s-IBM) represents a unique disease within idiopathic inflammatory myopathies with a dual myodegenerative-autoimmune physiopathology and a lack of an efficacious treat...
Missense...
The patient's phenotype includes symmetrical muscle wasting and weakness in the proximal parts of the limbs and axial muscles, a wide based gait, lordotic posture, positive Gowers' sign, mild calf enl...
The patients described experienced muscle wasting and weakness in the proximal and distal parts of the limbs which is a common finding in VCP related disease. Nevertheless, the patient has distinguish...
Sporadic inclusion body myositis (sIBM) is a distinct subcategory of Idiopathic Inflammatory Myopathies (IIM), characterized by unique pathological features such as muscle inflammation, rimmed vacuole...
Dysphagia is a common symptom of sporadic inclusion body myositis (IBM), affecting disease trajectory and patient quality-of-life. Despite this, it is considerably understudied. The purpose of this re...
Recent investigations confirm that dysphagia in IBM is a debilitating and complex symptom that warrants timely evaluation and management. Further, they highlight the lack of validation of standardized...
A paucity exists in the literature to effectively guide clinical decision-making for patients with IBM and dysphagia. Given this, it is our belief that a careful multidisciplinary and multipronged pat...
Inclusion body myositis (IBM), an inflammatory myopathy with progressive weakness without efficient treatment, typically presents after 45 years of age and younger patients are sparsely studied....
In a population-based study during a 33-year period, 142 patients with IBM were identified in western Sweden. Six patients fell outside the European Neuromuscular Centre 2011 criteria for IBM due to y...
The median age at symptom onset was 36 (range 34-45) years and at diagnosis 43 (range 38-58) years. Four patients were deceased at a median age of 59 (range 50-75) years. The median survival from diag...
Early-onset IBM is a severe disease, causing progressive muscle weakness, high muscle mitochondrial DNA mutation load and a reduced cumulative survival in young and middle-aged individuals....
To evaluate the validity, reliability, responsiveness and meaningful change threshold of the Inclusion Body Myositis (IBM) Functional Rating Scale (FRS)....
Data from a large 20-month multicentre, randomised, double-blind, placebo-controlled trial in IBM were used. Convergent validity was tested using Spearman correlation with other health outcomes. Discr...
Among the 150 patients, mean (SD) IBMFRS total score was 27.4 (4.6). Convergent validity was supported by medium to large correlations (r...
When administered by trained raters, the IBMFRS is a reliable, valid and responsive tool that can be used to evaluate the impact of IBM and its treatment on physical function, with a 2-point reduction...
NCT02753530....
Inclusion body myositis is the commonest acquired myopathy in those over 50 years of age. Although it is classified as an idiopathic inflammatory myopathy and the most frequent finding on muscle biops...
Throughout the twenty-first century, the view on inclusion bodies (IBs) has shifted from undesired by-products towards a targeted production strategy for recombinant proteins. Inclusion bodies can eas...
The objective of this study is to evaluate the frequency and characteristics of facial involvement in inclusion body myositis (IBM) patients and to compare it to the one previously described in facios...
Thirty-two IBM patients were included and compared to 29 controls and 39 FSHD patients. All participants were recorded in a video as they performed a series of seven facial tasks. Five raters independ...
IBM patients had higher FWS than controls (7.89 ± 7.56 vs 1.06 ± 0.88, p < 0.001). Twenty IBM patients (63%) had a facial weakness with a FWS above the maximum value for controls. All facial tasks wer...
This study enabled us to estimate the frequency of facial impairment in IBM in more than half of patients, to detail its characteristics and to compare them with those of FSHD patients. The standardiz...